K053019

510(K) SUMMARY

Submitter:	Guidant Corporation		
	Cardiac Rhythm Management (CRM)		
	4100 Hamline Avenue North		
	St. Paul, Minnesota 55112-5498		
Contact:	Jennifer X. Tang		
	Senior Regulatory Affairs Associate		
	Telephone: (800) 227-3422 or direct (651) 582-6746		
	FAX: (612) 582-5134		
	Email: jennifer.tang@guidant.com		
Date of Summary:	February 20, 2006		
Common Name:	Stylet		
Trade Name:	ACUITY™ Steerable Stylet Accessory		
Classification Name:	Class II		
	Per 21 CFR 870.1380, Catheter Stylet, Cardiovascular Panel		
Predicate:	 Firm Straight 0.016 Stylet, Model 6602, K905674, cleared January 30, 1991 		
	 Tapered 0.016 Stylet, Model 6583, K843060, cleared September 20, 1984 		

1.1. DEVICE DESCRIPTION

The ACUITY Steerable Stylet is intended for delivery of the ACUITY Steerable Lead in the coronary veins. The stylets come in either soft or standard stiffness, and in three lengths (to match the ACUITY Steerable Lead lengths).

The stylet consists of a stainless steel wire with a polypropylene knob/cap assembly at the proximal end. The distal end of the wire has a taper and terminates in a bullet shaped tip. Both soft and standard stylets have the same base wire diameter. The difference in stiffness is due to a slight difference in the diameter within the taper at the distal end of the wire.

1.2. Intended Use

For use with compatible, transvenous, left ventricular, pace/sense leads.

page 1 of 2

1.3. SUMMARY OF TECHNOLOGICAL CHARACTERISTICS

Comparisons of the ACUITY Steerable Stylet and the predicate devices show that the technological characteristics such as Intended Use, material, nominal diameter, assembly, dispensing hoop design, package pouch, sterilization method, sterilization indicator, and shelf life are substantially equivalent to the currently marketed predicate devices.

1.4. TESTING DATA

Testing demonstrated that the ACUITY Steerable Stylet met the acceptance criteria. No new safety or effectiveness issues were raised during the testing program. The ACUITY Steerable Stylet may be considered substantially equivalent to the predicate devices.

1.5. CONCLUSION

The Guidant ACUITY Steerable Stylets are substantially equivalent to the currently marketed Firm Straight 0.016 Stylet, Model 6602 (K905674, cleared 1/30/1991) and Tapered 0.016 Stylet, Model 6583 (K843060, cleared 9/20/1984).

K053019 page 2 of 2



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 3 2006

Guidant Corporation c/o Ms. Jennifer X. Tang Senior Regulatory Affairs Associate 4100 Hamline Avenue North St. Paul, MN 55112-5798

Re: K053019

Trade Name: ACUITYTM Steerable Stylet Accessory

Regulation Number: 21 CFR 870.1380 Regulation Name: Catheter Stylet

Regulatory Class: II (two)
Product Code: DRB

Dated: February 06, 2006 Received: February 07, 2006

Dear Ms. Tang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Page 2 – Ms. Jennifer X. Tang

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

S/fimmumar for

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

INDICATION FOR USE STATEMENT

510(k) Number (if known):	K053019			
Device Name:	ACUITY TM Steerable Stylet Accessory For use with compatible, transvenous, left ventricular, pace/sense leads			
Indications For Use:				
Prescription Use: X (Part 21 CFR 801 Subpart D	AND/OR	Over-The-Counter Use: (21 CFR 807 Subpart	C)	
(PLEASE DO NOT WRITE B	ELOW THIS LINE-CONTINU	JE ON ANOTHER PAGE IF NEEDED)) ——	

Concurrence of CDRH, Office of Device Evaluation (ODE)

Division of Caraiovascular Devices

510(k) Number k05 2019